Codexis vs Protalix BioTherapeutics
CDXS and PLX side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CDXS and PLX compare
Protalix BioTherapeutics is the larger company, worth 1.6 times as much as Codexis ($209M against $130M).
Codexis grew revenue faster over the last twelve months (35.9% versus 30.1% for Protalix BioTherapeutics).
Protalix BioTherapeutics keeps more of each dollar of sales as profit, with a net margin of 23.5% compared with −39.6% at Codexis.
Protalix BioTherapeutics scores higher on the StockData Score (17 against 5 for Codexis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CDXS | PLX |
|---|---|---|
| Size and price | ||
| Market cap | $130M | $209M |
| Share price | $1.19 | $2.59 |
| Change, 1 year | −50.8% | 9.3% |
| Change, 5 years | −97.0% | 133% |
| Beta (5Y) | 2.41 | 0.84 |
| Employees | 146 | 226 |
| StockData Score | ||
| Total score | 5 | 17 (better) |
| Valuation score | 1 | 5 (better) |
| Growth score | 2 | 2 |
| Performance score | 1 | 4 (better) |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 11.3× |
| P/S | 1.7× (better) | 2.6× |
| P/B | 4.0× | 2.9× (better) |
| EV/EBITDA | – | 7.8× |
| P/FCF | – | 27.2× |
| FCF yield | −9.3% | 3.7% (better) |
| Fair value | $1.22 | $5.46 |
| Margin of safety | 2.1% | 52.5% (better) |
| Growth | ||
| Revenue growth (TTM) | 35.9% (better) | 30.1% |
| Revenue growth, 5Y average | 0.38% (better) | −3.5% |
| Net income growth (TTM) | – | 202% |
| EPS growth (TTM) | – | 475% |
| Profitability | ||
| Gross margin | 87.0% (better) | 69.2% |
| Operating margin | −35.6% | 28.9% (better) |
| Net margin | −39.6% | 23.5% (better) |
| FCF margin | −15.7% | 9.5% (better) |
| Return on equity | −69.4% | 31.2% (better) |
| Return on invested capital | −91.8% | 49.5% (better) |
| Financial health | ||
| Debt / equity | 1.24 (better) | 0.00 |
| Current ratio | 3.06 (better) | 2.94 |
| Altman Z-score | −6.05 | 5.30 (better) |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 63.7% | 17.9% |
| Held by insiders | 2.2% | 4.6% |
| Insider net buying, 12 months | −$7.6M | $101K (better) |
| Short interest, % of float | 4.5% | 4.0% |
Go deeper
- CDXS stock overview
- CDXS income statement
- CDXS valuation and score
- PLX stock overview
- PLX income statement
- PLX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.